I'd put higher limits on DNDN's prospects. With an unrestricted approval by the FDA the pop would be over $30 but, more important, there's no reason for it to stay under $50 in the longer run. I think it isn't unreasonable to look for a triple from here.
It may be overly optimisitc, though, to look for an unrestricted approval.
Long August calls at $25 and $40...
Hard work often pays off over time,
but laziness always pays off right now.